Dual-target CAR-NK cells not checked
FollowEvery change as it happens, and a Monday email
Trials
8 active
8 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Route: IV infusion. Schedule: single infusion on Day 0; optional second infusion on Day 7 in the absence of dose-limiting toxicity (DLT) and with adequate clinical status.”In the company’s words, NCT07486089 on ClinicalTrials.gov
- Tested for
- HER2-positive Breast Cancer (2 trials), Non-Small Cell Lung Cancer (2 trials), Epithelial Ovarian Cancer (2 trials), Primary Peritoneal Carcinoma (2 trials), Fallopian Tube Carcinoma (2 trials), Recurrent or Refractory Disease After Standard Therapies (2 trials), Glioblastoma (2 trials), Malignant Glioma (2 trials) and 11 more
- Main trialPhase 1/2
- “This study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer. After a tumor antigen assessment (HER2/ERBB2, MUC1, ROR1, and in some TNBC cases mesothelin), each participant will receive the most suitable dual-target CAR-NK product for their tumor profile, following short-course lymphodepleting chemotherapy.”In the company’s words, NCT07486089 on ClinicalTrials.gov
- Other names
- Dual-target CAR-NK cell product
Other drugs for HER2-positive Breast Cancer
- D-0502InventisBio Co., Ltd · Phase 3
- ElacestrantStemline Therapeutics, Inc. · Phase 3
- YL202MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- SPH4336Shanghai Pharmaceuticals Holding Co., Ltd · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
- NiraparibGSK · Phase 3
Coming up8
- 14 Feb 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 14 Feb 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 17 Feb 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 18 Feb 2027Phase 1 trial completes · ClinicalTrials.gov
- 14 Mar 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 14 Mar 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 14 Apr 2027Phase 1 trial completes · ClinicalTrials.gov
- 14 Jun 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 14 Feb 2027 | Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) | |
| Phase 1/2Recruiting | 14 Feb 2027 | Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC | |
| Phase 1/2Recruiting | 17 Feb 2027 | Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) | |
| Phase 1/2Recruiting | 14 Mar 2027 | Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC | |
| Phase 1/2Recruiting | 14 Mar 2027 | Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC | |
| Phase 1/2Recruiting | 14 Jun 2027 | Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2 | |
| Phase 1Recruiting | 18 Feb 2027 | Dual-Targeting CAR-NK Cell Therapy for Recurrent/Progressive Glioblastoma and High-Grade Glioma | |
| Phase 1Recruiting | 14 Apr 2027 | Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026